HARROW HEALTH, INC.: insider trades · United States · SEC (Form 4)

About HARROW HEALTH, INC.

Harrow, Inc. (NASDAQ: HROW) is a United States-based ophthalmic healthcare company focused on eye disease management. Headquartered in Nashville, Tennessee, Harrow has evolved from its former identity as Imprimis Pharmaceuticals into a more specialized eye-care platform with a sharper strategic focus. That repositioning has helped the company build a business model centered on serving ophthalmologists, surgeons, and patients with chronic or procedure-related ocular conditions. Harrow’s core business is built around two complementary pillars: branded ophthalmic pharmaceuticals and compounded/specialty pharmacy products through ImprimisRx, its ophthalmic compounding platform. The company offers a portfolio spanning treatments used in cataract surgery, inflammation, dry eye, and retinal disease management. In addition to its commercially marketed products, Harrow has pursued selective licensing and portfolio expansion strategies to broaden its ophthalmology offering and improve access to therapies. More recently, the company has also added biosimilar ophthalmology rights and other specialty assets intended to strengthen its long-term commercial mix. From a competitive standpoint, Harrow occupies a differentiated niche in the U.S. eye-care market. Its hybrid model — combining compounded medicines, branded products, and commercialization rights — is uncommon and gives the company exposure to multiple layers of the ophthalmology value chain. This structure can support customer retention and commercial flexibility, while also making Harrow more specialized than diversified large-cap pharma peers. The company’s presence is primarily in the United States, where it focuses on building a national commercial footprint around ophthalmology practices, specialty pharmacies, and care providers. Recent developments underscore Harrow’s growth-oriented profile. In 2025, management reaffirmed a full-year revenue outlook in the $270–280 million range and highlighted continued execution across commercial and development programs. The company also reported formulary coverage gains and additional specialty pharmacy partnerships. Another notable strategic move came in 2025, when Harrow secured exclusive U.S. commercial rights to Samsung Bioepis ophthalmology biosimilars, including products referencing Lucentis and Eylea, which could deepen its position in retinal medicine. For investors, Harrow should be viewed as a focused ophthalmology platform listed on the U.S. NASDAQ market, with a business model tied to specialty healthcare demand, product execution, reimbursement dynamics, and ongoing pipeline/portfolio expansion.